Providing the best management for patients with bladder cancer relies on close cooperation among uro-oncologists and pathologists. The pathologist is involved in the diagnosis and assessment of prognostic and therapeutic factors in bladder biopsies, transurethral resection (TUR) and cystectomy specimens. The pathologist must report accurately the key features using terms that are well understood by clinicians. Adequate clinical information is important to pathologists in deciding the best approach in handling and processing the surgical specimens.
An open communication is essential for urooncologists and pathologists in the decision-making process for diagnosis and patient management (l). Adequate clinical information is important to pathologists in deciding the best approach in handling and processing the surgical specimens and directing the most essential information to be reported.
The specimen requisition form must contain relevant information which the clinician can provide (2, 3) . With differing implications for non-invasive papillary versus flat tumours and advent of enhanced cystoscopic visualization, the urologist's impression provides helpful information for the pathologist in difficult situations, such as when the entire lesion architecture is not obvious on the slides (e.g. fragmented or superficial sections).
Information on the surgical procedure, such as for surveillance or post intravesical therapy biopsies, initial or second TUR (e.g. for deep muscle assessment or completion of resection), "early" or salvage cystectomy, among others, is important for pathologists in specimen handling and reporting. Presence of calculi, catheterization or infection may explain reactive changes. Other relevant information includes history of bladder cancer and prior intravesical or neoadjuvant chemotherapy. This review deals with a contemporary update on pathology reporting for urinary bladder cancer. mucosal aspect of tissue fragmentsto allow embedding on edge and better visualization of the surface urothelium, although this may not always be possible.
For histologic evaluation, at least 3 levels of tissue sections for each biopsy should be prepared. Deeper levels into the block are recommended if the surface urothelium is deemed not entirely visible or in situations of denuded samples, particularly with known risk for carcinoma in situ (CIS), to exclude the possibility of denuded CIS.
Transurethral resections
The conventional way of processing TURs is to submit the tissue entirely. In large tumours exceeding 10 em, one approach is to submit 1 section per em of tumour diameter (up to 10 cassettes), and additional selective sampling until muscularis propria (MP) invasion is identified, or submitting the rest of the sample if no MP invasion is recognized after the first selective sampling.
The second TURs for deep muscle staging are typically low volume samples, which can be processed entirely. Large bulk completion TUR for incompletely resected tumours may have an option to submit less if the initial TUR has already established the diagnosis and attributed risk (e.g., pT2 stage).
Follow-up TUR for bladder-preservation treatment after chemotherapy and/or radiotherapy however should be processed the conventional way.
Cystectomy
After adequate fixation, samples must be taken from representative areas of the tumour, normalappearing bladder, the prostate, seminal vesicles, or other organs included in the surgical specimen. Minimum sections of the bladder should include at least the tumour/s, including its deepest penetration, and representative sections of the dome, trigone, anterior, posterior and lateral walls. In potential cystectomy with no residual tumour (pTO), prior surgical sites or mucosal ulcerations should be submitted entirely for any possible residual tumor.
Adequate mapping of different regions of the bladder should be performed, as well as in "early" cystectomy or in setting of post-neoadjuvant chemotherapy with less visible or no gross residual tumours. Any suspicious-looking areas of reddening and mucosal induration (for CIS) need to be sampled.
Grossly visible tumour in perivesical fat (PT3b) or at resection margins (R2) must be included in the gross examination. For tumour grossly invading the bladder wall, multiple full thickness sections including the area grossly suspicious for deepest penetration should be included in the sections to assess pT2a/b vs pT3a. The underlying soft tissue margin should be examined, inked and sampled. Unless submitted separately for frozen section, ureter and urethral margins should be sampled, preferably taken as shave cross sections so that the entire mucosal circumference can be visualized. In case of segmental cystectomy, bladder wall margins of resection should be identified for tumour involvement.
The alternative to partial sampling with regular cassettes is the complete sampling with the whole mount technique (Figs. la-Ie). Even though whole mounts of sections have been shown not to be superior to sections from standard blocks in detecting adverse pathological features, their use has the great advantage of displaying the architecture of the bladder and the identification and location of tumour nodules; furthermore, it is easier to compare the pathological findings with those obtained from cystoscopy, TUR and biopsies.
In cystoprostatectomy (CyP) specimens, right and left prostate should be inked differently and representative sections from both sides are to be taken including perpendicular sections of the apical margins, to secure assessment of important variables in case of concomitant prostate cancer, which is not an uncommon occurrence. Sections of the prostate should include the prostatic urethra to identify possible tumour invasion originating from a separate urethral carcinoma (pT2). Sections of possible deep penetration to prostate from bladder by the tumour should also be taken to document higher stage (pT4) bladder cancer. Likewise, tumour mass along the distal ureter/ureteral orifice should be closely examined, whether or not tumour is arising from the distal ureter, for appropriate staging. The whole mount technique can be used to sample the prostate from CyP specimens.
REPORTING OF SPECIMENS

Histological grade
Use of the 2004 WHO classification system is recommended (4, 5) . Based on institutional/clinician preference, other systems, in particular the 1973 WHO system, may be used alongside. Grading should also take cancer heterogeneity into consideration; approximately one-third of patients with pTa tumour had cancer containing a different histologic grade. Currently, grading of papillary urothelial tumours is typically based on the worst grade present.
Urothelial carcinoma variants
UC is known to show variant histologic features otherwise known also as divergent differentiation, with estimates ranging from 7% to 81% in series reporting differentiation patterns ofUCs (6, 7) .
UC with divergent differentiation has a worse prognosis when compared with pure urothelial cancer, although stage matched cohorts show limited differences. Billis et al. (8) in a study of 165 TUR cases noted that 7% of tumours showed squamous and/or glandular differentiation. Those patients with divergent differentiation had higher clinical stage at presentation compared to conventional UC (8). Wasco et al. (9) in a study of 448 consecutive TURs and 295 subsequent cystectomies, found that UCs with divergent differentiation were more likely to be muscularis propria invasive at TUR and extravesical fat invasive at cystectomy compared to pure urothelial cancers. Jozwicki et al. (10) performed mapping in 38 cystectomies, and then correlated the mapping studies with survival time, the presence of greater than 80% pure urothelial cancer within a specimen was a favourable prognostic factor, and increasing numbers of histologic subtypes (increasingly divergent differentiation) led to a less favourable prognosis.
Divergent morphology must be documented because of its prognostic implication. Furthermore, reporting facilitates correlation with subsequent metastasis, were it to occur at remote sites. When multiple divergent (aberrant) morphologies are present, one should provide relative percentages for each of the patterns, e.g., invasive UC (70%) with glandular (20%) squamous and (10%) differentiation.
Lymphovascular invasion
Lymphovascular invasion (LVI) usually appears as small groups of tumour cells in lymphatic or blood vessels. It may also fill the vascular space completely. LVI is an important prognostic factor in TUR and cystectomy specimens (11) (12) (13) (14) (15) (16) (17) (18) . It can predict tumour behaviour and guide treatment decisions when detected in TUR specimens (12) (13) (14) 18) . It was shown as predictor of poorer outcome including progression and metastasis in patients with Tl bladder cancer in TUR specimens (12, 14, 18) .
When LVI is identified in TUR it will be present in 65% of matched cystectomies and associated with nodal metastases in 41% of cases (13) . LVI was also shown to be an independent prognostic variable in bladder cancer patients treated with radical cystectomy (16, 17) . In a retrospective study of 750 patients with bladder cancer, LVI was shown to be an independent predictor of recurrence and decreased cause-specific and overall survival in node-negative invasive bladder cancer treated with cystectomy (15) . Thus, reporting for the presence of LVI is recommended in TURs and cystectomy specimens with invasive bladder cancer.
Strict criteria must be utilized in establishing a diagnosis of vascular invasion in UC because peritumoral stromal retraction is a common finding that often mimics a vascular space. Retraction artifact around nests of invasive carcinoma clusters often occur that can mimic LVI.
The use of immunohistochemistry (CD31, CD34, D2-40) (Fig. If) for the diagnosis of intravascular invasion in UC should be used only in selected histologically equivocal cases for confirmation.
The most important factor, however, that may deter its widespread reporting is the difficulty assessing LVI that may result in poor reproducibility, even using immunohistochemistry (19) .
Prostate involvement
In biopsies of prostate/prostatic urethra it is important to report the status of urethral mucosa (CIS or not), if prostatic glands are represented in the biopsy specimen and if so, whether they are involved by urothelial neoplasia or not. Involvement of the prostatic ducts and acini without stromal invasion is staged as pTis following the staging system for "Urothelial carcinoma of the Prostate".
Involvement of prostate may be through direct invasion from a bladder primary (pT4, staging system for "Urothelial carcinoma ofthe Bladder") or UC arising from the prostatic urethra with secondary prostatic stromal involvement or prostatic stromal invasion secondary to UC involving prostatic ducts and acini. In the two latter situations, the staging system for "Urothelial carcinoma of the Prostate" is adopted.
Cheville et al. (20) demonstrated that patients with prostatic UC involving prostatic stroma have a significantly poorer 5-year disease specific survival than patients with UC of the prostatic urethra. Shen et al. (21) showed that patients with prostatic CIS or urethral lamina propria invasion had a similar, but higher incidence of lymph node metastasis and lower long-term and 5-year survival than those patients without prostatic involvement. Similarly, prostatic stromal invasion and periprostatic/seminal vesical invasion had a similar, but much higher nodal metastasis and worse survival than patients with only prostatic CIS or urethral lamina propria invasion (21) .
It is apparent that an important explanation of the wide range of detection rates of prostatic stromal invasion in various series is the manner of examination and sampling of the prostate gland (22) .
Lymph nodes
Lymph nodes must be dissected from the lymphadenectomy specimens and all grossly and tentatively identified lymph nodes in the specimen should be submitted.
The minimum number of lymph nodes required in cystectomy specimen is not established. Recent studies have emphasized the importance of lymph node density (LND) for nodal staging. LND is defined by the ratio of positive lymph nodes to the total number of lymph nodes sampled, but again, the minimum number of lymph nodes in the specimen for optimal LND estimation has yet to be established (23) . Prior studies suggested that the number of lymph nodes, the size of tumor metastasis and the presence of extranodal extension have prognostic significance (15, 19, 24) Single-institution cystectomy series have shown for both node-negative and node-positive patients with invasive bladder cancer that overall survival improves with an increasing number of lymph nodes examined (24) . In a study by Fang et al. (25) , the minimum number of lymph node submission for radical cystectomy and pelvic lymphadenectomy was required, having to submit more tissue, including fat, if minimum number of 16 lymph nodes was not reached. In a span of 4 years, the median number of lymph node increased from 15 to 20, and this policy was found to decrease mortality risk by 48% and significant in multivariate analysis (15) .
Stephenson et al. (26) , showed the prognostic importance in measuring aggregate lymph node metastasis diameter. Fleischmann et al. (27) have recently shown that extracapsular extension oflymph node metastases defines a subgroup with a very poor prognosis.
Checklists
The recent literature is not short of satisfactory checklists and commentaries for handling and reporting genitourinary pathology specimens (28) (29) (30) (31) (32) (33) . Organizations such as the College of American Pathologists recommend reporting in a checklist! synoptic format and have outlined "essential" elements for reporting specimens resected for invasive bladder cancer (29) .
CONCLUSIONS
The most common tissue specimens encountered are biopsy and TUR, which provide the main information essential to prescribe a correct subsequent therapy for the patient that includes more aggressive treatment options.Additional information on curative-intent resections (e.g. cystectomy) determines the adequacy of therapy and appropriate surveillance or further need for surgery or adjuvant chemotherapy and/or radiotherapy (34) .
